Document is current
Any future updates will be listed below
-
Authors
Johri, Shreya https://orcid.org/0000-0002-2388-3913
Bi, Kevin
Titchen, Breanna M.
Fu, Jingxin https://orcid.org/0000-0002-4028-3661
Conway, Jake
Crowdis, Jett P.
Vokes, Natalie I. https://orcid.org/0000-0002-3766-5335
Fan, Zenghua
Fong, Lawrence https://orcid.org/0000-0002-6428-428X
Park, Jihye
Liu, David https://orcid.org/0000-0003-0346-5033
He, Meng Xiao
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA233100, R01CA227388)
U.S. Department of Defense (W81XWH-21-PCRP-DSA)
Prostate Cancer Foundation (PCF-Movember Challenge Award)
- License Information
-
More Information
Article History
Received: 8 December 2021
Accepted: 20 February 2025
First Online: 1 March 2025
Competing interests
: E.M.V.A. has received research support (to institution) from Novartis and BMS. E.M.V.A. serves as a consultant or on scientific advisory boards of Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, Monte Rosa. E.M.V.A. has equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa. E.M.V.A. receives travel reimbursements from Roche/Genentech. E.M.V.A. has filed institutional patents on chromatin mutations and immunotherapy response, and methods for clinical interpretation, and has intermittent legal consulting on patents for Foaley & Hoag. L.F. has received research support (to institution) from Roche/Genentech, Abbvie, Bavarian Nordic, Bristol Myers Squibb, Dendreon, Janssen, Merck, and Partner Therapeutics. L.F. has served on the scientific advisory boards of Actym, Allector, Astra Zeneca, Atreca, Bioalta, Bolt, Bristol Myer Squibb, Immunogenesis, Merck, Merck KGA, Nutcracker, RAPT, Scribe, Senti, Soteria, TeneoBio, and Roche/Genentech. M.X.H. is currently an employee of Genentech/Roche and has been a consultant to Amplify Medicines, Ikena Oncology, and Janssen. Work in this manuscript was performed when M.X.H. was a PhD student in the Biophysics program at Harvard Medical School. J.C. has been a consultant to Tango Therapeutics. He is also currently an employee of PathAI. N.I.V. serves on advisory boards of Sanofi and Oncocyte. The remaining Authors declare no competing interests.
